Work

Determination of MIC Quality Control Ranges for the Novel Gyrase Inhibitor Zoliflodacin

Year: 2019

Type: article

Abstract: This report describes the results of two different, multilaboratory quality control (QC) studies that were used to establish QC ranges for the novel gyrase inhibitor zoliflodacin against the ATCC strains recommended by the Clinical and Laboratory Standards Institute (CLSI).

Source: Journal of Clinical Microbiology

DOI: 10.1128/jcm.00567-19

Authors: Alita A. Miller, Maria M. Traczewski, Michael D. Huband, Patricia A. Bradford, John P. Mueller

Institutions: Entasis Therapeutics (United States), JMI Laboratories

Language: English

Topic: Bacterial Identification and Susceptibility Testing

Subfield: Clinical Biochemistry

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: Entasis Therapeutics